ClinicalTrials.gg
Status unknownNCT04593966DOPAUpdated Oct 20, 2020

Pediatric and Adult Cerebral Arteriovenous Malformation Neurofunctional Outcomes

An observational study in Cerebral Arteriovenous Malformation, sponsored by yuanli Zhao. Status unknown at 1 site in China. Open to participants aged 1 Year to 80 Years. Per ClinicalTrials.gov, last updated 2020-10-20.

Sponsored by yuanli Zhao · Observational

How we know

The sponsor has not verified this record recently (last verified Oct 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
1 Year to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Intracranial Arteriovenous Malformations with a site in China — 4 open to participants now, 4 under way, none of them phase 3. Intracranial Arteriovenous Malformations · China.

Started
2012
with 1 other
Observational
7 of 13
3 open now
Registered
7th of 13
by date
Lead sponsor
1 of 13
yuanli Zhao

Among the 13 studies in Intracranial Arteriovenous Malformations with a site in China, this one is one of 2 that started in 2012, is one of 7 observational ones, and was the 7th registered.

Intracranial Arteriovenous Malformations

43 studies on the registry are indexed under Intracranial Arteriovenous Malformations; 15 are open to participants now.

Browse Intracranial Arteriovenous Malformations studies →

Open to participants now

4 of the 13 studies in Intracranial Arteriovenous Malformations with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 13 Intracranial Arteriovenous Malformations studies recruiting now, 10 (77%) set no upper age limit and 2 (15%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.

This study: 1 Year to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Intracranial Arteriovenous Malformations with a site in China, or all of them as a file.
02

Study summary

Cerebral Arteriovenous malformations (AVMs) are abnormal tangles which are usually believed congenital. AVM can cause different symptoms depending on where it is located, but the most common symptoms are intracranial hemorrhage and seizure. Outcomes of AVM patients can be very different due to factors like the location of lesion, age, sex etc. Generally, more early the intervention was taken, the risk of adverse events would be lower. But the selection of surgical timing for pediatric AVM patients is hard to judge, due to children's cerebral vessels angioarchitecture can be still developing with their age. Some previous studies indicated that there is no difference in intervention outcomes between pediatric and adult AVM patients, so pediatric patients should undergo more aggressive intervention. DOPA study aims to compare the clinical intervention outcomes of both pediatric and adult patients with eloquent region cerebral arteriovenous malformations, helping to determine the treatment strategy.

Read the detailed description

Follow-up: In the investigators' neurosurgical center, follow-up was conducted for all participants at the first 3-6 months and annually after discharge by clinical visit and telephone interview.

Study overview: DOPA will aim on outcomes of both pediatric and adult AVMs patients who underwent intervention in investigators' institution. Intervention strategies contains microsurgical resection, embolization, embolization + radiosurgery, and single-stage hybrid surgery (embolization + resection). Outcomes will be measured by a neurologist using Modified Rankin Scale (mRs). Participants' mRs\<2 will be considered as a good outcome and investigators will keep follow-up with every patient for at least 3 years.

Sample size: About 300 patients will be enrolled in this study, and adults and children will account for half. All kinds of intervention will be included. The distribution of different strategies is excepted as: 30% resection, 20% embolization, 30% embolization + radiosurgery and 20% hybrid surgery.

Study endpoints: The patients' mRs, occlusion rate and complication will be evaluated at 2 weeks, discharge from hospital, 1 year and 3 years after the first-time intervention.

03

Conditions studied

  • Cerebral Arteriovenous Malformation
04

Who can participate

Ages eligible
1 Year to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with brain arteriovenous malformation which located in eloquent area.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The diagnosis of AVM was confirmed with digital subtraction angiography (DSA) and/or magnetic resonance imaging(MRI).
  • Patients had underwent interventions in our institution.
  • AVMs were located in eloquent area.

Exclusion criteria

Exclusion Criteria:

  • Patients with multiple AVMs.
  • Patients with hereditary hemorrhagic telangiectasia (HHT).
  • Patients with missing clinical and imaging data.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Pediatric AVM

    1. AVM patients' age under 18-years-old who underwent intervention in investigators' institution. 2. Patients' lesions were located in eloquent and confirmed by image.

  • Adult AVM

    1. AVM patients' age over 18-years-old who underwent intervention in investigators' institution. 2. Patients' lesions were located in eloquent and confirmed by image.

06

What researchers measure

Primary outcomes

  1. modified Ranking Scale score at 2 weeks after the operation

    The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms. No significant disability. Able to carry out all usual activities, despite some symptoms. Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. Moderate disability. Requires some help, but able to walk unassisted. Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. Severe disability. Requires constant nursing care and attention, bedridden, incontinent. Dead

    Time frame: 2 weeks

  2. modified Ranking Scale score when discharge

    The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms. No significant disability. Able to carry out all usual activities, despite some symptoms. Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. Moderate disability. Requires some help, but able to walk unassisted. Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. Severe disability. Requires constant nursing care and attention, bedridden, incontinent. Dead

    Time frame: Discharge (assessed up to 10 days)

  3. modified Ranking Scale score at 1 years after the operation

    The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms. No significant disability. Able to carry out all usual activities, despite some symptoms. Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. Moderate disability. Requires some help, but able to walk unassisted. Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. Severe disability. Requires constant nursing care and attention, bedridden, incontinent. Dead

    Time frame: 1 years

  4. modified Ranking Scale score at 3 years after the operation

    The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms. No significant disability. Able to carry out all usual activities, despite some symptoms. Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. Moderate disability. Requires some help, but able to walk unassisted. Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. Severe disability. Requires constant nursing care and attention, bedridden, incontinent. Dead

    Time frame: 3 years

Secondary outcomes

  1. Obliteration rate

    Confirmed by postoperative DSA or MRI/magnetic resonance angiography

    Time frame: At least 1 year, up to 3 years

07

Study locations

1 of 1 sites recruiting
  • Capital medical university affiliated Beijing Tiantan hospital
    Beijing, Beijing 101100, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2012 (actual). Primary completion is estimated for Nov 2024, 151 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2020
First posted
Oct 20, 2020
StartActual
Apr 1, 2012
Primary completionEst.
Nov 2024
CompletionEst.
Dec 2024
Last update
Oct 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04593966
Lead sponsor
yuanli Zhao
Collaborators
Peking University International Hospital
Responsible party
yuanli Zhao (Chairman of Neurosurgical center, Beijing Tiantan Hospital) — Sponsor-investigator
First posted
Oct 20, 2020
Start date
Apr 1, 2012
Primary completion
Nov 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Oct 20, 2020

Study contacts

Ruinan Li, MD
Contact
70akagi@gmail.com
+8618511287842
Yuanli Zhao, MD
Contact
zhaoyuanli@126.com
+8601069006284

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion